AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27475339 — intervention group
Group type: COMPARATOR
Intervention: Waiting control arm
Number of subjects: 925
Study 24896266 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy (MT)
Number of subjects: 15
Study 24896266 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 15
Study 24896266 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 15
Study 24896266 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PTCA) without stent
Number of subjects: 15
Study 24896266 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (BMS)
Number of subjects: 15
Study 24896266 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (DES)
Number of subjects: 15
Study 22233510 — intervention group
Group type: EXPERIMENTAL
Intervention: Op Volle Kracht (OVK) intervention, consisting of 16 lessons of 50 min each, incorporating Cognitive Behavioral Therapy, social skills training, problem solving, and decision making.
Number of subjects: 0
Study 22233510 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control condition)
Number of subjects: 0
Study 20579510 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release fluvoxamine (fluvoxamine ER) 100 mg/d, titrated to 100-300 mg/d
Number of subjects: 0
Study 20579510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20579510 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release fluvoxamine (fluvoxamine ER) during 40-week open-label extension
Number of subjects: 0
Study 20579510 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in OCD severity at 12 weeks
Number of subjects: 0
Study 18321791 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate (0.4 to 7.2 microg/kg)
Number of subjects: 44
Study 16104906 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose thalidomide (200 mg)
Number of subjects: 14
Study 16104906 — intervention group
Group type: COMPARATOR
Intervention: High-dose thalidomide (800 mg to 1200 mg)
Number of subjects: 14
Study 12559480 — intervention group
Group type: EXPERIMENTAL
Intervention: 200‐mg L‐5‐hydroxytryptophan
Number of subjects: 24
Study 12559480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10424679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fabric material stroked across the test site (VELVET, COTTON, PLASTIC MESH) at various velocities (0.5, 5, and 50 cm/s)
Number of subjects: 0
Study 10424679 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity of motion (0.5, 5, and 50 cm/s)
Number of subjects: 0
Study 10424679 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication of stimulus
Number of subjects: 0
Study 7750006 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietaria antigen
Number of subjects: 26
Study 7750006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2242106 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (4 to 5 mg per kilogram of body weight per day)
Number of subjects: 217
Study 2242106 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (after tapering and discontinuation)
Number of subjects: 217
Study 2242106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 400110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg three times daily for 10 days
Number of subjects: 99
Study 400110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1000 mg three times daily for 10 days
Number of subjects: 99
Study 30521129 — intervention group
Group type: EXPERIMENTAL
Intervention: PUR0200 (3 μg tiotropium)
Number of subjects: 0
Study 30521129 — intervention group
Group type: COMPARATOR
Intervention: Spiriva HH (18 μg)
Number of subjects: 0
Study 26991917 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + 0.8 mg folic acid
Number of subjects: 20702
Study 26991917 — intervention group
Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 20702
Study 26991917 — intervention group
Group type: COMPARATOR
Intervention: Enalapril alone (MTHFR TT genotype)
Number of subjects: 20702
Study 26991917 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + 0.8 mg folic acid (MTHFR TT genotype with low folate levels)
Number of subjects: 20702
Study 25645353 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD level reduction
Number of subjects: 397
Study 25645353 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD level as a continuous variable determined by flow cytometry
Number of subjects: 397
Study 24352403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified, NT-proBNP-guided therapy
Number of subjects: 499
Study 24352403 — intervention group
Group type: COMPARATOR
Intervention: Symptom-guided therapy
Number of subjects: 499
Study 23053645 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 420
Study 23053645 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg
Number of subjects: 420
Study 23053645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 23053645 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg and 900 mg
Number of subjects: 420
Study 19775450 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (O) 10 mg p.o. plus azasetron (A) 10 mg i.v. and dexamethasone (D) 10 mg i.v. on day 1; O 10 mg once a day on days 2‐5
Number of subjects: 229
Study 19775450 — intervention group
Group type: COMPARATOR
Intervention: Control group (A 10 mg i.v. and D 10 mg i.v. on day 1; D 10 mg i.v. once a day on days 2‐5)
Number of subjects: 229
Study 17530963 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-land strength training (S)
Number of subjects: 21
Study 17530963 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted- and assisted-sprint (RAS)
Number of subjects: 21
Study 17530963 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 21
Study 15296584 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Start program (experimental group)
Number of subjects: 54
Study 15296584 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 11402109 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose botulinum toxin type A (50 U)
Number of subjects: 133
Study 11402109 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose botulinum toxin type A (100 U)
Number of subjects: 133
Study 11402109 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 133
Study 9250554 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem CD 180 mg once/day
Number of subjects: 172
Study 8112440 — intervention group
Group type: EXPERIMENTAL
Intervention: LTE4
Number of subjects: 20
Study 8112440 — intervention group
Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 20
Study 8112440 — intervention group
Group type: COMPARATOR
Intervention: LTC4
Number of subjects: 20
Study 3318957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Intervention Dietary Group (reduction in dietary fat intake)
Number of subjects: 49
Study 3318957 — intervention group
Group type: COMPARATOR
Intervention: Control Dietary Group (dietary fat intake unchanged)
Number of subjects: 49
Study 31710340 — intervention group
Group type: EXPERIMENTAL
Intervention: TPI-287 (6.3 mg/m2 for AD, 20.0 mg/m2 for 4RT)
Number of subjects: 68
Study 31710340 — intervention group
Group type: EXPERIMENTAL
Intervention: TPI-287
Number of subjects: 68
Study 31710340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 30289569 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-implant mucositis
Number of subjects: 275
Study 30289569 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-implantitis
Number of subjects: 275
Study 30289569 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants with bone level ≥2 mm without BOP
Number of subjects: 275
Study 30289569 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-implant diseases overall
Number of subjects: 275
Study 30289569 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistically significant associations for peri-implantitis
Number of subjects: 275
Study 26863867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified physiotherapy program consisting of endurance and muscle force exercises
Number of subjects: 60
Study 26863867 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 60
Study 25240705 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W), up-titrated to 150 mg Q2W if LDL-C ≥70 mg/dL after 8 weeks
Number of subjects: 966
Study 25240705 — intervention group
Group type: COMPARATOR
Intervention: Alirocumab 75 mg every 2 weeks (Q2W)
Number of subjects: 966
Study 22153132 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0 μg with 0.17% ropivacaine 12 mL
Number of subjects: 102
Study 22153132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 50 μg with 0.17% ropivacaine 12 mL
Number of subjects: 102
Study 22153132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 75 μg with 0.17% ropivacaine 12 mL
Number of subjects: 102
Study 22153132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 100 μg with 0.17% ropivacaine 12 mL
Number of subjects: 102
Study 20669311 — intervention group
Group type: EXPERIMENTAL
Intervention: CEP-1347 (antiapoptotic agent)
Number of subjects: 806
Study 20669311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 806
Study 20669311 — intervention group
Group type: EXPERIMENTAL
Intervention: CEP-1347
Number of subjects: 806
Study 17179874 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of a treatment fidelity instrument
Number of subjects: 0
Study 17179874 — intervention group
Group type: EXPERIMENTAL
Intervention: Possibilities Project Psychotherapy Coding Questionnaire
Number of subjects: 0
Study 16344433 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for choroidal melanoma
Number of subjects: 2320
Study 11873007 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg)
Number of subjects: 280
Study 11873007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 9876212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of rifampicin, co-trimoxazole and isoniazid (CotrifazidTM, CF) for 5 days
Number of subjects: 61
Study 9876212 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine or pyrimethamine/sulphadoxine (control)
Number of subjects: 61
Study 9876212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of rifampicin, co-trimoxazole and isoniazid (CotrifazidTM, CF)
Number of subjects: 61
Study 7675568 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training (8 sessions over 4 weeks)
Number of subjects: 21
Study 7675568 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 21
Study 7675568 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 2123901 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative strategy in tertiary hospitals
Number of subjects: 1461
Study 2123901 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy in community hospitals
Number of subjects: 1461
Study 2123901 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative strategy
Number of subjects: 1461
Study 6994679 — intervention group
Group type: EXPERIMENTAL
Intervention: New synthetic dressing
Number of subjects: 0
Study 6994679 — intervention group
Group type: COMPARATOR
Intervention: Conventional topical chemotherapeutic agent
Number of subjects: 0
Study 31650480 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week moderate-intensity physical activity intervention
Number of subjects: 46
Study 29956903 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) combined with psychological intervention (PI)
Number of subjects: 120
Study 29956903 — intervention group
Group type: COMPARATOR
Intervention: Psychological intervention (PI)
Number of subjects: 120
Study 29956903 — intervention group
Group type: COMPARATOR
Intervention: Electro-acupuncture (EA)
Number of subjects: 120
Study 29956903 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) plus psychological intervention (PI)
Number of subjects: 120
Study 25774566 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg twice daily
Number of subjects: 168
Study 25774566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 23062523 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus 6 months of daily educational text messages
Number of subjects: 659
Study 23062523 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 659
Study 21957161 — intervention group
Group type: EXPERIMENTAL
Intervention: Social technology restriction
Number of subjects: 21
Study 19300157 — intervention group
Group type: EXPERIMENTAL
Intervention: Enucleation and hydroxyapatite implantation (group 2)
Number of subjects: 100
Study 19300157 — intervention group
Group type: COMPARATOR
Intervention: Evisceration with scleral quadrisection and alloplastic implantation (group 1)
Number of subjects: 100
Study 17713334 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated food item (0.5 mg fluoride cookie, 3 times daily)
Number of subjects: 10
Study 17713334 — intervention group
Group type: COMPARATOR
Intervention: Placebo food item (cookie, 3 times daily)
Number of subjects: 10
Study 17713334 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with fluoride-free toothpaste
Number of subjects: 10
Study 15025742 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim (160 mg orally twice daily for 3 days)
Number of subjects: 9
Study 15025742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11780763 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicatechin gallate (ECg)
Number of subjects: 10
Study 11780763 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin (EGC)
Number of subjects: 10
Study 11780763 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate (EGCg)
Number of subjects: 10
Study 11780763 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant activity (FRAP)
Number of subjects: 10
Study 11780763 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid levels
Number of subjects: 10
Study 9517735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 140
Study 9517735 — intervention group
Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 140
Study 8002338 — intervention group
Group type: EXPERIMENTAL
Intervention: serial sun‐like UV irradiation
Number of subjects: 74
Study 3903156 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical heparin
Number of subjects: 0
Study 3903156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30829132 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete intraureteral stent placement
Number of subjects: 80
Study 30829132 — intervention group
Group type: COMPARATOR
Intervention: Conventional stent placement
Number of subjects: 80
Study 29191819 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg weekly
Number of subjects: 36
Study 29191819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 26169711 — intervention group
Group type: EXPERIMENTAL
Intervention: PLT mass-based transfusion guideline
Number of subjects: 100
Study 26169711 — intervention group
Group type: COMPARATOR
Intervention: PLT count-based transfusion guideline
Number of subjects: 100
Study 24469222 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 1200
Study 24469222 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 1200
Study 22468755 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic air (F(I)O(2) = 100%)
Number of subjects: 10
Study 22468755 — intervention group
Group type: COMPARATOR
Intervention: Normoxic air
Number of subjects: 10
Study 20499120 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training (NF), 36 sessions
Number of subjects: 94
Study 20499120 — intervention group
Group type: COMPARATOR
Intervention: Computerised attention skills training (AST)
Number of subjects: 94
Study 17658415 — intervention group
Group type: EXPERIMENTAL
Intervention: Three weeks of hand-based splinting
Number of subjects: 26
Study 17658415 — intervention group
Group type: COMPARATOR
Intervention: Free active motion
Number of subjects: 26
Study 17175572 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 8
Study 17175572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15494617 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 6 to 12 mg/day
Number of subjects: 0
Study 15494617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11192137 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Number of subjects: 52
Study 11192137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2% ophthalmic solution
Number of subjects: 52
Study 11192137 — intervention group
Group type: COMPARATOR
Intervention: Placebo (natural tears lubricant eye drop)
Number of subjects: 52
Study 11192137 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine and nedocromil
Number of subjects: 52
Study 8922004 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tetracaine (4 mL)
Number of subjects: 57
Study 8922004 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (4 mL)
Number of subjects: 57
Study 1556948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (600 kcal/d, 8 g nitrogen/d)
Number of subjects: 16
Study 1556948 — intervention group
Group type: COMPARATOR
Intervention: Nonketogenic diet (600 kcal/d, 8 g nitrogen/d)
Number of subjects: 16
Study 1556948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 16
Study 1556948 — intervention group
Group type: COMPARATOR
Intervention: Nonketogenic diet
Number of subjects: 16
Study 3998203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 0
Study 3998203 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30303299 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived line managers' support during the initiation and active phase
Number of subjects: 159
Study 30303299 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the initiation and active phase
Number of subjects: 159
Study 30303299 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the initiation phase
Number of subjects: 159
Study 30303299 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived line managers' support in the active phase
Number of subjects: 159
Study 30303299 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the active phase
Number of subjects: 159
Study 28485544 — intervention group
Group type: EXPERIMENTAL
Intervention: TC-325
Number of subjects: 20
Study 28485544 — intervention group
Group type: COMPARATOR
Intervention: CCT
Number of subjects: 20
Study 25642687 — intervention group
Group type: EXPERIMENTAL
Intervention: rMV (100Hz, 300‐500 μm; three applications per day, each lasting 10 minutes, for 3 consecutive days)
Number of subjects: 40
Study 25642687 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation on contracted quadriceps (NV=non vibrated group)
Number of subjects: 40
Study 24787529 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction to gesture
Number of subjects: 42
Study 24787529 — intervention group
Group type: COMPARATOR
Intervention: No gesture instruction (Control)
Number of subjects: 42
Study 23180062 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 0
Study 23180062 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0
Study 23180062 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19733827 — intervention group
Group type: EXPERIMENTAL
Intervention: Closer 'distance' to the PPMW scenario
Number of subjects: 0
Study 19733827 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitute products (drugs in the same therapeutic class)
Number of subjects: 0
Study 19733827 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust ratings for pharmacists and physicians
Number of subjects: 0
Study 19733827 — intervention group
Group type: COMPARATOR
Intervention: Trust scores based on 'distance' from PPMW
Number of subjects: 0
Study 16956912 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 1784
Study 16956912 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine
Number of subjects: 1784
Study 15132375 — intervention group
Group type: EXPERIMENTAL
Intervention: Small incision trabeculectomy avoiding Tenon's capsule (SIT)
Number of subjects: 60
Study 15132375 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with Mitomycin-C (MMC)
Number of subjects: 60
Study 11281475 — intervention group
Group type: EXPERIMENTAL
Intervention: Coughing
Number of subjects: 39
Study 11281475 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva
Number of subjects: 39
Study 9040628 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized cyclosporine A (300 mg) for 10 consecutive days followed by maintenance of 3 days per week
Number of subjects: 16
Study 9040628 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized cyclosporine A
Number of subjects: 16
Study 9040628 — intervention group
Group type: COMPARATOR
Intervention: Conventional rescue therapy
Number of subjects: 16
Study 7702337 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil infusion during arteriographies
Number of subjects: 16
Study 3312030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (2 g b.i.d.)
Number of subjects: 67
Study 3312030 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (2 g t.i.d. or more)
Number of subjects: 67
Study 3312030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 67
Study 3312030 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 67
Study 3312030 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67